Press Release: Sanofi’s Sarclisa subcutaneous approved in the EU as the first anticancer treatment administered via an on-body injector

Sanofi’s Sarclisa subcutaneous approved in the EU as the first anticancer treatment administered via an on-body injectorSarclisa administered via ...
The American Journal of Managed Care

Will Subcutaneous PD-1/PD-L1 Inhibitors Be a Game Changer?

With Bristol Myers Squibb (BMS) now rolling out the SC version of rival nivolumab (Opdivo Qvantig), the shift from 30-minute intravenous (IV) infusion to 5-minute SC injection could be one of the most ...